Skip to main content
Equibles
NEO logo

NEO · Neogenomics Inc · Metrics

Track NEO — free

Use NEO with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research NEO.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$17.99 +0.72 (+4.17%) At close · Oct 28 Q2 2026 earnings call transcript
S&P 600 member Russell 2000 member Rebalance outlook locked
Market Cap
$2.22B
Shares
128.48M
Volume · Oct 28 2.58M Avg daily vol (3M) 2.18M

NEO metrics

93 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$17.99
Market cap
$2.22B

Price action

20 metrics
Price change (1W)
+3.9%
Price change (30D)
-10.5%
Price change (3M)
+28.9%
Price change (6M)
+91.5%
Price change (YTD)
+46.9%
Price change (1Y)
+70.0%
Trailing year
Price change (5Y)
-61.1%
52-week high
$19.91
52-week low
$7.19
Change from 52-week high
-13.3%
Change from 52-week low
+140.2%
Annualized volatility
53.5%
Annualized volatility (3M)
59.3%
Beta
1.1
RSI (14D)
51.1
Price vs SMA 50
-1.9%
Price vs SMA 200
+35.9%
Avg volume (3M)
2.18M
Relative volume
1.3
Average dollar volume
$37.37M

Company

3 metrics
Sector
Healthcare
Industry
Diagnostics & Research
Shares outstanding
128.48M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
3.1×
reciprocal yield 32.2%
EV / EBITDA
1,995.9×
reciprocal yield 0.1%
EV / EBIT
—
P / sales
2.8×
reciprocal yield 35.7%
P / book
2.7
reciprocal yield 36.6%
FCF yield
-0.3%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
97.2
reciprocal yield 1.0%
Earnings yield
-2.4%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
2.7×
reciprocal yield 36.4%
EV / revenue historical average (5Y)
3.9×
reciprocal yield 25.8%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
2026-10-28
Last earnings
2026-07-28

Profitability

9 metrics
Gross margin
43.9%
Operating margin
-8.9%
Trailing 12 months
Net margin
-6.8%
Gross profit (TTM)
$336.53M
Operating profit (TTM)
−$68.44M
Net income (TTM)
−$51.88M
Trailing 12 months
Diluted EPS (TTM)
$-0.24
FCF margin
-1.0%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$5.93
Gross profit per diluted share (TTM)
$2.60
Operating profit per diluted share (TTM)
$-0.53
EBITDA per diluted share (TTM)
$0.02
Net income per diluted share (TTM)
$-0.40
Operating cash flow per diluted share (TTM)
$0.17
Free cash flow per diluted share (TTM)
$-0.06
Capital expenditures per diluted share (TTM)
$0.23
R&D per diluted share (TTM)
$0.30
Stock compensation per diluted share (TTM)
$0.28
Book value per share
$6.49

Growth

11 metrics
Revenue growth YoY
+11.2%
Year over year
Net income growth YoY
—
Revenue (TTM)
$766.29M
Trailing 12 months
EPS growth YoY
-300.0%
Shares change YoY
+2.3%
Year over year · more shares
Revenue CAGR (3Y)
+12.6%
Revenue CAGR (5Y)
+10.4%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-6.6%
Return on assets
-3.8%
Debt / equity
0.5
Current ratio
3.6
EBITDA (TTM)
$1.09M
Free cash flow (TTM)
−$7.36M
Quick ratio
3.3
Interest coverage
-26.5
Net debt / EBITDA
37.7
Return on invested capital
—
Trailing 12 months
Net cash
−$234.44M
Latest balance sheet
Cash & equivalents
$145.54M
Total assets
$1.35B
Total debt
$379.98M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$22.05M
Capital expenditures (TTM)
$29.40M
R&D (TTM)
$38.17M
SG&A (TTM)
—
Stock compensation (TTM)
$36.20M
R&D / revenue
5.0%
Stock compensation / revenue
4.7%

Ownership (13F)

9 metrics
13F filers
269
13F filer change QoQ
+14
Institutional ownership
120.0%
Conviction holders (share of 13F filers)
1.9%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+10.2%
Holder tenure
12.2
Price vs estimated holder cost
+36.9%

Ownership (registered funds)

1 metrics
Index-fund ownership
36.4%

Short interest

3 metrics
Short interest
11.1%
Latest settlement · 6.0 days to cover
Days to cover
6.0d
Short-squeeze score
80 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$321,400
Insider-sentiment score
43 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1077183 CUSIP 64049M209 13F (30d) 57 filings 57 filers Visit website Investor relations